Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Login | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock 1-2 weeks - Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Buhlak, Shafeek ; Abad, Nadeem ; Akachar, Jihane , et al. Pharmaceuticals,2025,18(2):233. DOI: 10.3390/ph18020233
More
Abstract: Background/Objectives: Glioblastoma multiforme (GBM), an aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment due to its resistance to current therapies and poor prognosis. This study aimed to synthesise and evaluate 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, designed to enhance druggability and solubility, and to investigate their potential as VEGFR2 inhibitors for GBM treatment. Methods: The synthesised compounds were analysed using in silico methods, including molecular docking and dynamics studies, to assess their interactions with key residues within the VEGFR2 binding pocket. In vitro evaluations were performed on U87-MG and U138-MG GBM cell lines using MTT assays to determine the IC50 values of the compounds. Results: Among the tested compounds, 4u (IC50 = 7.96 μM), 4t (IC50 = 10.48 μM), 4m (IC50 = 4.20 μM), and 4q (IC50 = 8.00 μM) demonstrated significant antiproliferative effects against both the U87-MG and U138-MG cell lines. These compounds exhibited markedly higher efficacy compared to temozolomide (TMZ), which showed IC50 values of 92.90 μM and 93.09 μM for U87-MG and U138-MG, respectively. Molecular docking and dynamics studies confirmed strong interactions between the compounds and VEGFR2 kinase, supporting their substantial anti-cancer activity. Conclusions: This study highlights the promising potential of 3,4-dihydroquinolin-2(1H)-one analogues, particularly 4m, 4q, 4t, and 4u, as VEGFR2-targeting therapeutic agents for GBM treatment. Further detailed research is warranted to validate and expand upon these findings.
Keywords: glioblastoma multiforme ; 3,4-dihydroquinolin-2(1H)-one ; therapeutic efficacy ; molecular docking ; molecular dynamics ; VEGFA–VEGFR2 pathway ; anti-cancer
Purchased from AmBeed: 613-45-6 ; 98-03-3 ; 54197-66-9 ; 104-88-1
CAS No. : | 98-03-3 | MDL No. : | MFCD00005429 |
Formula : | C5H4OS | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | CNUDBTRUORMMPA-UHFFFAOYSA-N |
M.W : | 112.15 | Pubchem ID : | 7364 |
Synonyms : |
|
Chemical Name : | Thiophene-2-carbaldehyde |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H227-H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
[ 13679-70-4 ]
5-Methylthiophene-2-carbaldehyde
Similarity: 0.97
[ 5834-16-2 ]
3-Methyl-2-thiophenecarboxaldehyde
Similarity: 0.82
[ 24445-35-0 ]
5-(Methylthio)thiophene-2-carbaldehyde
Similarity: 0.79
[ 5834-16-2 ]
3-Methyl-2-thiophenecarboxaldehyde
Similarity: 0.82
[ 5834-16-2 ]
3-Methyl-2-thiophenecarboxaldehyde
Similarity: 0.82
感谢您访问我们的网站,您可能还对以下资源感兴趣:
成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天